- Alumis Inc. recently reported positive Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib in moderate-to-severe plaque psoriasis, showing strong skin clearance, quality-of-life gains, and a generally well-tolerated safety profile, and it now plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026.
- A particularly interesting angle for investors is envudeucitinib’s high rates of scalp psoriasis clearance and rapid itch relief, which could help differentiate it among oral TYK2 inhibitors and support Alumis’ broader immunology pipeline, including its ongoing systemic lupus erythematosus program.
- We’ll now explore how these Phase 3 psoriasis data and the planned FDA submission shape Alumis’ investment narrative and risk-reward profile.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
What Is Alumis' Investment Narrative?
For Alumis, the big-picture belief is that envudeucitinib can become a cornerstone franchise in immunology, anchoring a still-early commercial story. The strong ONWARD1/2 results and the planned 2026 NDA filing meaningfully sharpen the near-term catalyst path, giving investors clearer line of sight to a first potential product while also reinforcing the rationale for the lupus program. At the same time, the company remains loss-making, has leaned on equity issuance and an at-the-market program, and faces trial, regulatory, and execution risks that could matter more now that expectations are higher after a very large 12‑month share price move. The recent data readout slots directly into this tension: it strengthens the scientific case, but also raises the stakes if anything slips on timelines or safety.
But the biggest near-term risk many investors might miss is not scientific at all. Upon reviewing our latest valuation report, Alumis' share price might be too optimistic.Exploring Other Perspectives
Fair value estimates from three Simply Wall St Community members range widely, from just above US$2 to almost US$40, showing how far apart views can be. When you set that against Alumis’ reliance on future envudeucitinib milestones and ongoing clinical spend, it underlines why different investors may focus on very different risks and potential outcomes for the business.
Explore 3 other fair value estimates on Alumis - why the stock might be worth less than half the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Alumis research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- Our free Alumis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alumis' overall financial health at a glance.
Looking For Alternative Opportunities?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Find 63 companies with promising cash flow potential yet trading below their fair value.
- The latest GPUs need a type of rare earth metal called Neodymium and there are only 27 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com